Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative sintilimab in MSI-H/dMMR or PD-L1-high gastric/GEJ adenocarcinoma
ChiCTR2300073854Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Tumor regression grade 0/1 (TRG 0/1). Started Jul 2023; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300073854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073854.